Resultados: 2

Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

England. National Institute for Health and Care Excellence.

This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). No new clinical evidence was reviewed. Treatments for BRCA mutation-positive hormone-relapsed meta...

Neoplasias da Próstata/tratamento farmacológico, Mutação/efeitos dos fármacos, Proteína BRCA1, Antineoplásicos Hormonais/uso terapêutico

Texto completo

Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

England. National Institute for Health and Care Excellence.

Evidence-based recommendations on mobocertinib (EXKIVITY) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. Commercial arrangement There is a simple discount patient access scheme for mobocertinib. NHS organisations ca...

Inibidores de Proteínas Quinases/uso terapêutico, Neoplasias Pulmonares/tratamento farmacológico, Platina/uso terapêutico, Mutação/efeitos dos fármacos, Fator de Crescimento Epidérmico/antagonistas & inibidores

Texto completo